Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

NCT03829462 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

377

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: Regorafenib
DRUG: Irinotecan

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle